Staccato Applications-Focused Workstations - Zymark Automation Achieves Unparalleled Success
Zymark Corporation's Staccato Workstations are becoming industry standard for pharmaceutical laboratories, with unparalleled success that is taking the drug discovery world by storm. Zymark received its first order for a Staccato in June 2000, only one month after the product's official launch, with more bookings quickly following. Total Staccato related revenues reached $6 million by the end of 2000.
Over six major pharmaceutical companies have already integrated the Staccato into their laboratories. In addition, several cooperative alliances involving Staccato have been established.
"Staccato was made possible through Zymark's acquisition of Scitec in the early part of 1999," stated Zymark Corporation President and CEO Kevin Hrusovsky. "The open architecture software Scitec had developed is what allows us to offer Staccato's rapid assembly of finished automation-ready pieces. The pairing with Zymark's new advanced liquid handler, SciClone, enabled Staccato to become the fastest growing product in Zymark's 20-year history.
"In addition, the creation of this remarkably dexterous line of workstations demanded an exceptional amount of teamwork from customers and third party technology providers. Their assistance was indispensable, with the end result is that the same basic hardware and software configurations are able to perform a vast amount of laboratory procedures, ranging from DNA purification and preparations to cell based/enzymatic assays, plate replications and cherry picking."
"What makes Staccato unique is that Zymark consolidates our offerings around what we know scientists really want, while we simultaneously help them minimize their overhead costs," voiced Edward M. Alderman, Ph.D., Director of Pharmaceutical Research at Zymark Corporation. "Staccato is able to employ only the highly versatile devices that are most often used to accomplish specific goals in laboratory environments, regardless of the vendor, and simply integrate them into fully automated systems."
Staccato applications-focused workstations provide a uniform architecture using reliable, economical and standard building blocks. At the heart of the Staccato workstations are the SciClone liquid handling and Zymark's storage technologies. Coupled with CLARA 2000 software and optional accessories, these workstations become scalable, cost-effective automation tools with unmatched flexibility, throughput and capacity that are ready for production right out of the box. For information about Staccato Workstations and other Zymark Corporation products, visit www.zymark.com.
Zymark Corporation, headquartered in Hopkinton, MA, impacts the world by advancing the ability to discover, develop, and market safe and effective drugs that can lengthen and improve the quality of life for everyone. Zymark's employees are active in more than 35 countries and their combined expertise in Pharmaceutical Analysis and Laboratory Automation makes Zymark one of the world's leading suppliers in this application area.